Cargando…
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016
This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477277/ https://www.ncbi.nlm.nih.gov/pubmed/28649381 http://dx.doi.org/10.1186/s40425-017-0253-2 |
| _version_ | 1783244758628433920 |
|---|---|
| author | Adusumilli, Prasad S. Cha, Edward Cornfeld, Mark Davis, Thomas Diab, Adi Dubensky, Thomas W. Evans, Elizabeth Grogan, Jane L. Irving, Bryan A. Leidner, Rom S. Olwill, Shane A. Soon-Shiong, Patrick Triebel, Frederic Tuck, David Bot, Adrian Dansey, Roger D. Drake, Charles G. Freeman, Gordon J. Ibrahim, Ramy Patel, Salil Chen, Daniel S. |
| author_facet | Adusumilli, Prasad S. Cha, Edward Cornfeld, Mark Davis, Thomas Diab, Adi Dubensky, Thomas W. Evans, Elizabeth Grogan, Jane L. Irving, Bryan A. Leidner, Rom S. Olwill, Shane A. Soon-Shiong, Patrick Triebel, Frederic Tuck, David Bot, Adrian Dansey, Roger D. Drake, Charles G. Freeman, Gordon J. Ibrahim, Ramy Patel, Salil Chen, Daniel S. |
| author_sort | Adusumilli, Prasad S. |
| collection | PubMed |
| description | This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy. |
| format | Online Article Text |
| id | pubmed-5477277 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-54772772017-06-23 New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016 Adusumilli, Prasad S. Cha, Edward Cornfeld, Mark Davis, Thomas Diab, Adi Dubensky, Thomas W. Evans, Elizabeth Grogan, Jane L. Irving, Bryan A. Leidner, Rom S. Olwill, Shane A. Soon-Shiong, Patrick Triebel, Frederic Tuck, David Bot, Adrian Dansey, Roger D. Drake, Charles G. Freeman, Gordon J. Ibrahim, Ramy Patel, Salil Chen, Daniel S. J Immunother Cancer Review This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy. BioMed Central 2017-06-20 /pmc/articles/PMC5477277/ /pubmed/28649381 http://dx.doi.org/10.1186/s40425-017-0253-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Review Adusumilli, Prasad S. Cha, Edward Cornfeld, Mark Davis, Thomas Diab, Adi Dubensky, Thomas W. Evans, Elizabeth Grogan, Jane L. Irving, Bryan A. Leidner, Rom S. Olwill, Shane A. Soon-Shiong, Patrick Triebel, Frederic Tuck, David Bot, Adrian Dansey, Roger D. Drake, Charles G. Freeman, Gordon J. Ibrahim, Ramy Patel, Salil Chen, Daniel S. New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016 |
| title | New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016 |
| title_full | New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016 |
| title_fullStr | New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016 |
| title_full_unstemmed | New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016 |
| title_short | New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016 |
| title_sort | new cancer immunotherapy agents in development: a report from an associated program of the 31(st)annual meeting of the society for immunotherapy of cancer, 2016 |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477277/ https://www.ncbi.nlm.nih.gov/pubmed/28649381 http://dx.doi.org/10.1186/s40425-017-0253-2 |
| work_keys_str_mv | AT adusumilliprasads newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT chaedward newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT cornfeldmark newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT davisthomas newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT diabadi newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT dubenskythomasw newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT evanselizabeth newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT groganjanel newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT irvingbryana newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT leidnerroms newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT olwillshanea newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT soonshiongpatrick newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT triebelfrederic newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT tuckdavid newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT botadrian newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT danseyrogerd newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT drakecharlesg newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT freemangordonj newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT ibrahimramy newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT patelsalil newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 AT chendaniels newcancerimmunotherapyagentsindevelopmentareportfromanassociatedprogramofthe31stannualmeetingofthesocietyforimmunotherapyofcancer2016 |